HIMS vs DUOL Comparison: AI Score, Valuation, Performance and Upside
DUOL holds the edge across 3 of 5 key metrics in this comparison. DUOL leads on both 1-year return (-48.64%) and forward P/E quality (20.36x vs 29.03x for HIMS), a relatively favorable combination of momentum and valuation. On fundamentals, HIMS is growing revenue faster (38.20%), while DUOL maintains the higher operating margin (11.68%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for HIMS (+7.36%) than for DUOL (-13.67%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | HIMS | DUOL |
|---|---|---|
| AI scorei | 42.5 | 32.1 |
| AI ranki | #844 | #2057 |
| Latest closei | $29.35 | $149.42 |
| 1M returni | -13.11% | +2.25% |
| 6M returni | +30.68% | +49.79% |
| 1Y returni | -49.24% | -48.64% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HIMS | DUOL |
|---|---|---|
| 1Y ago | $5.09K (-49.1%) started 2025-09-22 | $4.83K (-51.7%) started 2025-09-22 |
| 5Y ago | $35.53K (+255.3%) started 2021-09-21 | $7.4K (-26.0%) started 2021-09-22 |
| 10Y ago | $29.95K (+199.5%) started 2019-09-13 | $11.13K (+11.3%) started 2021-07-28 |
Hypothetical — past performance does not guarantee future results.
| Metric | HIMS | DUOL |
|---|---|---|
| Market capi | $6.79B | $7.25B |
| Trailing P/Ei | N/A | 18.39 |
| Forward P/Ei | 29.03 | 20.36 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 2.85 | 5.42 |
| Analyst targeti | $31.23 | $134.29 |
| Target upsidei | +7.36% | -13.67% |
| Metric | HIMS | DUOL |
|---|---|---|
| Revenue growthi | 38.20% | 18.30% |
| Earnings growthi | N/A | -27.50% |
| EPS growthi | N/A | -27.50% |
| FCF margini | +32.95% | +26.22% |
| Operating margini | -12.75% | 11.68% |
| Profit margini | -5.51% | 35.88% |
| ROIC proxyi | -32.03% | 34.42% |
| Return on equityi | -32.03% | 34.42% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | 0.00% | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 2.42 | 0.88 |
| Debt/equityi | 477.13 | 6.11 |
| Current ratioi | 0.93 | 2.72 |
| Quick ratioi | 0.82 | 2.51 |
Over the past year, HIMS and DUOL have moved weakly in the same direction (correlation of 0.23), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HIMS | DUOL |
|---|---|---|---|
| 1Y | Growthi | -49.13% | -51.70% |
| CAGRi | -49.25% | -51.77% | |
| Volatilityi | 91.81% | 63.24% | |
| Sharpe ratioi | -0.35 | -0.90 | |
| Sortino ratioi | -0.54 | -1.14 | |
| Max drawdowni | 76.86% | 74.07% | |
| Current drawdowni | 53.23% | 56.97% | |
| Avg drawdowni | 48.79% | 54.39% | |
| Ulcer Indexi | 51.76% | 57.93% | |
| Max daily dropi | 16.03% | 25.49% | |
| Max wkly dropi | 32.71% | 28.24% | |
| 5Y | Growthi | +255.33% | -25.98% |
| CAGRi | +28.87% | -5.84% | |
| Volatilityi | 84.22% | 65.67% | |
| Sharpe ratioi | 0.67 | 0.17 | |
| Sortino ratioi | 1.04 | 0.24 | |
| Max drawdowni | 78.88% | 83.35% | |
| Current drawdowni | 57.30% | 72.36% | |
| Avg drawdowni | 32.10% | 38.80% | |
| Ulcer Indexi | 37.32% | 46.02% | |
| Max daily dropi | 34.63% | 25.49% | |
| Max wkly dropi | 39.06% | 31.98% | |
| 10Y | Growthi | +199.49% | +11.30% |
| CAGRi | +16.91% | +2.10% | |
| Volatilityi | 77.59% | 66.06% | |
| Sharpe ratioi | 0.53 | 0.29 | |
| Sortino ratioi | 0.82 | 0.43 | |
| Max drawdowni | 87.29% | 83.35% | |
| Current drawdowni | 57.30% | 72.36% | |
| Avg drawdowni | 43.67% | 37.81% | |
| Ulcer Indexi | 52.12% | 45.34% | |
| Max daily dropi | 34.63% | 25.49% | |
| Max wkly dropi | 39.06% | 31.98% |
| Category | HIMS | DUOL |
|---|---|---|
| Company | HIMS | DUOL |
| Sector | Healthcare | Technology |
| Industry | Drug Manufacturers - Specialty & Generic | Software - Application |
| Core business | Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of… | Duolingo, Inc. operates as a mobile learning platform in the United States, the United Kingdom, and internationally. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.